Multipotent Amniotic Fetal Stem Cells: A Novel Source of Human Stem Cells
Valuable source of multipotent cells with extensive therapeutic potential. Unhampered source of human stem cells—no political or ethical obstacles. Can be propagated in an undifferentiated state in culture for long periods of time (about 60 doublings) and are able to differentiate into all three primary germ cells. Cells also appear to be devoid of tumorgenic properties.
Scientists at UC San Diego have developed methods for isolating, identifying, expanding, and differentiating a novel source of epithelioid multipotent amniotic fetal stem cells with typical hES markers. The isolated stem cells have been characterized and have been shown to express typical hES-cell markers (characterized by expression of SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, Oct-4, CD105, and SSEA1). The technology provides a method for preparing multipotent stem cells from amniotic fluid and includes harvesting from amniotic fluid; culturing, identifying, and isolating epithelioid stem-cells; and expanding the cells to an undifferentiated state. The number of differentiated pathways and the control of these pathways in culture suggest widespread applications of the new cells.
Patent Number: US7569385B2
Application Number: US2004918739A
Inventor: Haas, Martin
Priority Date: 14 Aug 2003
Priority Number: US7569385B2
Application Date: 13 Aug 2004
Publication Date: 4 Aug 2009
IPC Current: C12N000500 | A01N000102 | C12N0005073 | C12N0005074 | C12N000510 | G01N003348 | G01N003350 | G06F001900
US Class: 435325 | 435402 | 435455
Assignee Applicant: The Regents of the University of California
Title: Multipotent amniotic fetal stem cells
Usefulness: Multipotent amniotic fetal stem cells
Summary: The composition and methods are useful for growing stem cell lines that can create differentiated cells, such as specific cell types or tissue types, which are capable of being transplanted into an individual. The cells may be used to treat e.g. cirrhosis of the liver, diabetes, Parkinson's disease, stroke, burns, heart disease, cancer, osteoarthritis and Alzheimer's disease. A large number of other diseases are disclosed in the specification.
Novelty: New composition comprising multipotent or pluripotent stem cells derived from amniotic fluid, useful in cell replacement therapy or for treating diseases such as diabetes, Parkinson's disease, stroke, burns, heart disease or cancer
Disease Diagnostic/Treatment
Cancer/Tumor
7569385
Intellectual Property Information See U.S. Letters Patent 7,569,385. Tech ID/UC Case 19481/2005-041-0 Related Cases 2005-041-0, 2005-042-2
USA

